Kamada Ltd. (TLV: KMDA)
Israel
· Delayed Price · Currency is ILS · Price in ILA| Market Cap | 1.15B |
| Revenue (ttm) | 581.99M |
| Net Income (ttm) | 56.75M |
| Shares Out | 57.48M |
| EPS (ttm) | 0.94 |
| PE Ratio | 21.16 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 18,123 |
| Open | 1,961.00 |
| Previous Close | 1,982.00 |
| Day's Range | 1,961.00 - 1,982.00 |
| 52-Week Range | 1,685.00 - 2,329.00 |
| Beta | 0.25 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 14, 2024 |
About Kamada
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMR... [Read more]
News
Kamada Ltd. (KMDA) Q2 2024 Earnings Call Transcript
Kamada GAAP EPS of $0.08, revenue of $42.5M
Kamada Q2 2024 Earnings Preview
Kamada to Announce Second Quarter and First Half Ended June 30, 2024 Financial Results and Host Conference Call on August 14, 2024
REHOVOT, Israel, and HOBOKEN, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed produc...
Kamada Ltd. (KMDA) Q1 2024 Earnings Call Transcript
Kamada Ltd. (NASDAQ:KMDA) Q1 2024 Earnings Conference Call May 8, 2024 8:30 AM ET Company Participants Brian Ritchie - Investor Relations, LifeSci Advisors, LLC Amir London - Executive Officer Chaime...
Kamada Reports Strong First Quarter 2024 Financial Results with Year-Over-Year Top-Line Growth of 23% and a 96% Increase in Profitability; Raises Full-Year Financial Guidance
REHOVOT, Israel and HOBOKEN, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products...
Kamada to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
REHOVOT, Israel and HOBOKEN, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products...
Kamada Ltd. (KMDA) Q4 2023 Earnings Call Transcript
Kamada Ltd. (NASDAQ:KMDA) Q4 2023 Results Earnings Conference Call March 6, 2024 8:30 AM ET
Kamada Issues 2024 CEO Letter to Shareholders
REHOVOT, Israel, and HOBOKEN, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed produ...
Kamada Reports Strong Fiscal Year and Fourth Quarter 2023 Financial Results, and Provides Full-Year 2024 Guidance Representing Double-Digit Growth in Revenue and Profitability
REHOVOT, Israel, and HOBOKEN, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed produ...
Kamada to Announce Fourth Quarter and Fiscal Year 2023 Financial Results, and Provide 2024 Financial Guidance on March 6, 2024
REHOVOT, Israel, and HOBOKEN, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd.
Kamada: Kedrion Deal Locks In Growth
Kamada is a profitable specialty plasma company with a strong balance sheet and significant capital available for investment. The company has announced an expanded commercial agreement for its anti-ra...
KEDRION ANNOUNCES AN EIGHT-YEAR EXTENSION OF THE DISTRIBUTION AGREEMENT WITH KAMADA IN THE US FOR KEDRAB®
Since 2018 Kedrion has had exclusive distribution rights in the US for KEDRAB®, a Human Rabies Immune Globulin (HRIG) developed in partnership with Kamada Ltd. New agreement becomes effective in Janua...
Kamada Announces its Largest Commercial Agreement; A Strategic Engagement with Kedrion for U.S. Distribution of KEDRAB® including $180 Million of Revenues Over First Four Years
REHOVOT, Israel and HOBOKEN, N.J., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed product...
Celebrating Seeking Alpha's New Analysts - November 2023 Edition
In November, we welcomed 24 new analysts who published their first article on Seeking Alpha. This series highlights and welcomes these newcomers to our ranks of analysts who share their unique insight...
Kamada: Solid Specialty Plasma Play
Kamada is a profitable specialty plasma company with a strong balance sheet and significant capital available for investment. The company is expected to grow EBITDA significantly in the coming years t...
Kamada Ltd. (KMDA) Q3 2023 Earnings Call Transcript
Kamada Ltd. (NASDAQ:KMDA) Q3 2023 Earnings Conference Call November 13, 2023 8:30 AM ET Company Participants Brian Ritchie - IR, LifeSci Advisors Amir London - Chief Executive Officer Chaime Orlev - ...
Kamada Reports Significant Increase in Sales and Profitability in the Third Quarter and Nine Month 2023; Reiterates 2023 Revenue and Profitability Guidance
REHOVOT, Israel and HOBOKEN, N.J., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed product...
Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2023 Financial Results and Host Conference Call on November 13, 2023
REHOVOT, Israel, and HOBOKEN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indic...
Kamada Provides Corporate Update on its Israel Operations
REHOVOT, Israel, and HOBOKEN, N.J., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed produc...
These Israeli pharmaceutical stocks are down in the wake of Hamas attack
Shares of Israeli pharmaceutical companies took a hit in premarket trades Monday after Hamas' attack on Israel.
Kamada Announces Shareholder Approval and Planned Closing of $60 Million Private Placement with FIMI Opportunity Funds
REHOVOT, Israel and HOBOKEN, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed product...
Kamada Ltd. (KMDA) Q2 2023 Earnings Call Transcript
Kamada Ltd. (NASDAQ:KMDA) Q2 2023 Earnings Conference Call August 16, 2023 8:30 AM ET Company Participants Brian Ritchie - IR, LifeSci Advisors Amir London - CEO Chaime Orlev - CFO Conference Call Pa...
Kamada Reports Strong Second Quarter and First Half 2023 Financial Results; Reiterates 2023 Revenue and Profitability Guidance
REHOVOT, Israel and HOBOKEN, N.J., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed product...
Kamada to Announce Second Quarter and First Half Ended June 30, 2023 Financial Results and Host Conference Call on August 16, 2023
REHOVOT, Israel and HOBOKEN, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indica...